Smith Wade S, Sung Gene, Saver Jeffrey, Budzik Ronald, Duckwiler Gary, Liebeskind David S, Lutsep Helmi L, Rymer Marilyn M, Higashida Randall T, Starkman Sidney, Gobin Y Pierre, Frei Donald, Grobelny Thomas, Hellinger Frank, Huddle Dan, Kidwell Chelsea, Koroshetz Walter, Marks Michael, Nesbit Gary, Silverman Isaac E
Department of Neurology, University of California, San Francisco, 505 Parnassus Avenue, San Francisco, CA 94143-0114, USA.
Stroke. 2008 Apr;39(4):1205-12. doi: 10.1161/STROKEAHA.107.497115. Epub 2008 Feb 28.
Endovascular mechanical thrombectomy may be used during acute ischemic stroke due to large vessel intracranial occlusion. First-generation MERCI devices achieved recanalization rates of 48% and, when coupled with intraarterial thrombolytic drugs, recanalization rates of 60% have been reported. Enhancements in embolectomy device design may improve recanalization rates.
Multi MERCI was an international, multicenter, prospective, single-arm trial of thrombectomy in patients with large vessel stroke treated within 8 hours of symptom onset. Patients with persistent large vessel occlusion after IV tissue plasminogen activator treatment were included. Once the newer generation (L5 Retriever) device became available, investigators were instructed to use the L5 Retriever to open vessels and could subsequently use older generation devices and/or intraarterial tissue plasminogen activator. Primary outcome was recanalization of the target vessel.
One hundred sixty-four patients received thrombectomy and 131 were initially treated with the L5 Retriever. Mean age+/-SD was 68+/-16 years, and baseline median (interquartile range) National Institutes of Health Stroke Scale score was 19 (15 to 23). Treatment with the L5 Retriever resulted in successful recanalization in 75 of 131 (57.3%) treatable vessels and in 91 of 131 (69.5%) after adjunctive therapy (intraarterial tissue plasminogen activator, mechanical). Overall, favorable clinical outcomes (modified Rankin Scale 0 to 2) occurred in 36% and mortality was 34%; both outcomes were significantly related to vascular recanalization. Symptomatic intracerebral hemorrhage occurred in 16 patients (9.8%); 4 (2.4%) of these were parenchymal hematoma type II. Clinically significant procedural complications occurred in 9 (5.5%) patients.
Higher rates of recanalization were associated with a newer generation thrombectomy device compared with first-generation devices, but these differences did not achieve statistical significance. Mortality trended lower and the proportion of good clinical outcomes trended higher, consistent with better recanalization.
对于因颅内大血管闭塞导致的急性缺血性卒中,可采用血管内机械取栓术。第一代MERCI装置实现的再通率为48%,据报道,当与动脉内溶栓药物联合使用时,再通率可达60%。取栓装置设计的改进可能会提高再通率。
多中心MERCI研究是一项国际多中心、前瞻性、单臂试验,纳入症状发作8小时内接受治疗的大血管卒中患者进行取栓治疗。纳入静脉注射组织纤溶酶原激活剂治疗后仍存在大血管闭塞的患者。一旦新一代(L5 Retriever)装置可用,研究人员被指示使用L5 Retriever开通血管,随后可使用旧一代装置和/或动脉内组织纤溶酶原激活剂。主要结局为目标血管再通。
164例患者接受了取栓治疗,131例最初使用L5 Retriever治疗。平均年龄±标准差为68±16岁,基线时美国国立卫生研究院卒中量表评分中位数(四分位间距)为19(15至23)。使用L5 Retriever治疗使131条可治疗血管中的75条(57.3%)成功再通,辅助治疗(动脉内组织纤溶酶原激活剂、机械取栓)后131条中有91条(69.5%)成功再通。总体而言,良好的临床结局(改良Rankin量表评分0至2)发生率为36%,死亡率为34%;这两个结局均与血管再通显著相关。16例患者(9.8%)发生有症状性脑出血;其中4例(2.4%)为Ⅱ型脑实质血肿。9例(5.5%)患者发生具有临床意义的手术并发症。
与第一代装置相比,新一代取栓装置的再通率更高,但这些差异未达到统计学意义。死亡率呈下降趋势,良好临床结局的比例呈上升趋势,这与更好的再通情况一致。